UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 77

Sortiert nach

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

Journal of clinical oncology, 2014-01, Vol.32 (1), p.44-50

2014

Link zum Volltext

Verfügbarkeit prüfen

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial

Cancer chemotherapy and pharmacology, 2022-01, Vol.89 (1), p.93-103

2022

Link zum Volltext

Verfügbarkeit prüfen

Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers

PloS one, 2017-12, Vol.12 (12), p.e0189953-e0189953

2017

Link zum Volltext

Verfügbarkeit prüfen

Development and Validation of an ERCC1 Immunohistochemistry Assay for Solid Tumors

Archives of pathology & laboratory medicine (1976), 2016-12, Vol.140 (12), p.1397-1403

2016

Link zum Volltext

Verfügbarkeit prüfen

Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models

mAbs, 2021-01, Vol.13 (1), p.1954136-1954136

2021

Link zum Volltext

Verfügbarkeit prüfen

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo

PloS one, 2018-01, Vol.13 (1), p.e0191046-e0191046

2018

Link zum Volltext

Verfügbarkeit prüfen

55 Exploring proximal biomarkers of CBL-B inhibition in human peripheral blood mononuclear cells

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A64-A64

2023

Link zum Volltext

Verfügbarkeit prüfen

Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer

Cancer research (Chicago, Ill.), 2005-08, Vol.65 (16), p.7081-7085

2005

Link zum Volltext

Verfügbarkeit prüfen

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Cancer Research and Treatment, 2018, 50(2), , pp.398-404

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of Nano Clay on Corrosion Protection of Zinc-rich Epoxy Coatings on Steel 37

Journal of materials science & technology, 2016-11, Vol.32 (11), p.1152-1160

2016

Link zum Volltext

Verfügbarkeit prüfen

Microsatellite instability at tetranucleotide repeats in skin and bladder cancer

Oncogene, 2002-07, Vol.21 (32), p.4894-4899

2002

Link zum Volltext

Verfügbarkeit prüfen

Allelic Loss at Drosophila Patched Gene Is Highly Prevalent in Basal and Squamous Cell Carcinomas of the Skin

Journal of investigative dermatology, 2006-05, Vol.126 (5), p.1152-1158

2006

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.218-218

2020

Link zum Volltext

Verfügbarkeit prüfen

ANALYSIS OF AIR POLLUTION PARTICULATE-MEDIATED OXIDANT STRESS IN ALVEOLAR MACROPHAGES

Journal of Toxicology and Environmental Health, Part A, 1998-08, Vol.54 (7), p.529-545

1998

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

Gynecologic oncology, 2012-10, Vol.127 (1), p.63-69

2012

Link zum Volltext

Verfügbarkeit prüfen

Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer

Future oncology (London, England), 2021-10, Vol.17 (29), p.3781-3785

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4535: Automated image analysis algorithm development for cell surface-binding therapeutic agent target & its comparison to manual pathology scoring

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4535-4535

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB337: Inhibition of the E3 ligase CBL-B enhances the effector function and proliferation of natural killer cells

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB337-LB337

2023

Link zum Volltext

Verfügbarkeit prüfen

Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships

Journal of clinical pharmacology, 2015-03, Vol.55 (3), p.336-347

2015

Link zum Volltext

Verfügbarkeit prüfen

Carcinogen exposure and gene promoter hypermethylation in bladder cancer

Carcinogenesis (New York), 2006-01, Vol.27 (1), p.112-116

2006

Link zum Volltext

Verfügbarkeit prüfen

Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer

Future oncology (London, England), 2021-10, Vol.17 (29), p.3781-3785

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

Investigational new drugs, 2014-06, Vol.32 (3), p.489-499

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(71)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial

Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers

Development and Validation of an ERCC1 Immunohistochemistry Assay for Solid Tumors

Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo

55 Exploring proximal biomarkers of CBL-B inhibition in human peripheral blood mononuclear cells

Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor

Effect of Nano Clay on Corrosion Protection of Zinc-rich Epoxy Coatings on Steel 37

Microsatellite instability at tetranucleotide repeats in skin and bladder cancer

Allelic Loss at Drosophila Patched Gene Is Highly Prevalent in Basal and Squamous Cell Carcinomas of the Skin

Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial

Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers

ANALYSIS OF AIR POLLUTION PARTICULATE-MEDIATED OXIDANT STRESS IN ALVEOLAR MACROPHAGES

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer

Abstract 4535: Automated image analysis algorithm development for cell surface-binding therapeutic agent target & its comparison to manual pathology scoring

Abstract LB337: Inhibition of the E3 ligase CBL-B enhances the effector function and proliferation of natural killer cells

Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships

Carcinogen exposure and gene promoter hypermethylation in bladder cancer

Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

Suchergebnisse filtern